Ostex International Inc., of Seattle, began proceedingsto compel arbitration with Boehringer Mannheim GmbH,of Germany. Ostex wants to confirm termination of itslicense and distribution, and research and developmentagreements with Boehringer because, it alleged,Boehringer failed to meet marketing obligations forOsteomark kits in the microtiter plate format.

Cytogen Corp., of Princeton, N.J., signed letters ofintent with CIS bio international (CIS), of France, tomarket OncoScint CR/OV, an imaging agent to detectovarian and colorectal cancers, in Europe and other areasoutside North America; and with Faulding (Canada) Inc.,of Montreal, to market the product in Canada.

PerSeptive Biosystems Inc., of Framingham, Mass.,entered into an alliance with Germany-based BoehringerMannheim GmbH giving the companies co-exclusiverights to distribute PerSeptive's POROS chromatographycolumns worldwide. Boehringer will make a $2 millionequity investment, at $12.69 per share.

* AMDL Inc., of Tustin, Calif., received clearance inCanada to market its DR-70 tumor-marker kit fordetection of lung cancer.

* Incstar Corp., of Stillwater, Minn., launched its second-generation Parathyroid Hormone-related Protein assay.

* Biopool International Inc., of Ventura, Calif., receivedFDA approval to market five new chemistry reagentsystems.

(c) 1997 American Health Consultants. All rights reserved.